VolitionRx Limited (NYSE American: VNRX) has entered into a collaboration with Sysmex (TYO: 6869) to optimize the Nu.Q® NETs H3.1 assay on Sysmex's diagnostic platform. This partnership supports Volition's strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies, leveraging their disease expertise, regulatory capabilities, and installed analyzer base to accelerate development and commercialization. The collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases.
The Nu.Q® NETs assay is designed to detect neutrophil extracellular traps (NETs), which are implicated in various inflammatory and thrombotic conditions. Volition believes the assay could provide improved diagnostic information, support patient monitoring, and address a commercial opportunity with an estimated total addressable market of $3.8 billion. By partnering with Sysmex, Volition aims to expedite the assay's development and regulatory approval, ultimately bringing it to market more efficiently.
VolitionRx is a multi-national company focused on advancing the science of epigenetics. The company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
Sysmex Corporation is a global leader in clinical laboratory testing and diagnostic solutions, with a strong presence in hematology, coagulation, and urinalysis. The collaboration with Volition leverages Sysmex's expertise in diagnostic platform development and its extensive global distribution network. This partnership is expected to enhance the development of the Nu.Q® NETs assay, potentially leading to improved patient outcomes in diseases where NETosis plays a critical role.
For more information about VolitionRx and its technology, visit https://volition.com/. The full press release is available at https://ibn.fm/TSMG4.
